Our founders/owners, Ronnie Wallin and Henri Hansson, are both pharmacists from Uppsala University and since the start of the company in 1999 pharmaceutical development has been our key competence.

In 2003 Galenica had the honour of welcoming Nils-Olof Lindberg as Senior Scientist/Project Manager. His contribution at Galenica is not just impressive for its duration (over 20 years); what truly stands out is that he embarked on Galencia’s journey after retiring from Pfizer at the age of 66. Throughout his remarkable 60-year career, which continues to flourish, Nils-Olof has been a pivotal figure in the field of galenic pharmacy and the development of solid dosage forms. At Galenica, he is the mastermind behind several commercialized products, among them a product we developed for a customer a decade ago, significantly aiding those suffering from Addison’s disease.

In recognition of his invaluable achievements, we have established the Nils-Olof Lindberg Scholarship in Pharmacy. This initiative is a testament to Galenica’s commitment to fostering the aspirations of future pharmaceutical students.

We are excited to announce that the scholarship will be open for applications February-April every year. We encourage all aspiring pharmacy students to seize this opportunity and apply for The Nils-Olof Lindberg Scholarship in Pharmacy. The next application will open 2026-02-01.

We are thrilled to announce that Shno Asad has been awarded the 2025 Nils-Olof Lindberg Scholarship in Pharmacy, following a unanimous decision by Galenica’s jury. The scholarship, amounting to 50,000 SEK, will support her ongoing research at Uppsala University focused on bioconjugated nanoparticles for targeted diagnostics in inflammatory bowel disease (IBD).

Shno recently completed her PhD in Pharmaceutical Science at Uppsala University. Her work combines advanced drug formulation with clinical relevance and exemplifies the innovation and dedication that this scholarship celebrates. Galenica is proud to support Shno Asad on her continued scientific journey.

Nils-Olof has worked about 60 years within the Swedish pharmaceutical industry. The first 20 years in the Astra Group in Lund (Draco, Astra-Draco), followed by 19 years in Helsingborg in the Pharmacia Group (Leo, Pharmacia, Pfizer) and 20 years in Malmö (Galenica).

His main fields of expertise are formulation of solid dosage forms, preformulation with powder characterization, scale up and technology transfer.

Additionally other objects have been:

• Application of chemometrics (Lund, Helsingborg, Malmö)
• Application of intelligent software in formulation (Helsingborg, Malmö)
• Effervescent tablets (Lund, Helsingborg)
• Formulation and production considering containment (Helsingborg)
• Wet granulation – batch wise and continuous; instrumentation (Lund, Helsingborg)
• Technology transfer, sites abroad (Helsingborg).

Nils-Olof also participated in the organization of the international tablet symposia arranged by Apotekarsociteten.